Binimetinib
Binimetinib is in phase III clinical trials for the treatment of metastatic or unresectable cutaneous melanoma with NRAS mutations and low grade serous ovarian, fallopian tube or peritoneum cancer.
Binimetinib was originally developed by Array BioPharma, then licensed to Novartis for worldwide development in 2010. But Array Biopharma regained full worldwide rights of the product in 2015. And in 2015, Pierre Fabre acquired exclusive rights to commercialize the product.
General Information
Update Date：2016-02-01
- Drug Name：
- Binimetinib
- Research Code：
- MEK-162; ARRY-162; ARRY-438162
- Trade Name：
- MOA：
- MEK inhibitor
- Indication：
- NRAS mutant melanoma; Ovarian cancer; Fallopian tube cancer; Peritoneum cancer
- Status：
- Phase III (Active)
- Company：
- Array (Originator) , Novartis,Pierre Fabre
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-08-19
|
Molecular Weight | 441.23 | ||||||||||||
| Formula | C17H15BrF2N4O3 | |||||||||||||
| CAS No. | 606143-89-9 (Binimetinib); | |||||||||||||
| Chemical Name | 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide | |||||||||||||
| Binimetinib （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||
Synthesis & Impurities
Update Date：2016-01-28
1. WO2014063024A1 / US20140128442A1.
2. WO2007002157A2 / US8039637B2.